Alnylam Pharmaceuticals, Inc.
General ticker "ALNY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $42.8B (TTM average)
Alnylam Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 38.5%.
Estimated limits based on current volatility of 2.5%: low 317.06$, high 333.50$
Factors to consider:
- Total employees count: 2230 as of 2024
- US accounted for 3.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Product commercialization failure, Operational and conduct risks, Labor/talent shortage/retention, Supply chain disruptions, Regulatory and compliance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [283.26$, 501.55$]
- 2026-12-31 to 2027-12-31 estimated range: [262.11$, 473.58$]
Financial Metrics affecting the ALNY estimates:
- Negative: with PPE of 99.0 at the end of fiscal year the price was high
- Positive: 7.68 < Operating profit margin, % of 13.51
- Positive: Investing cash flow per share per price, % of 0.83 > -0.65
- Positive: 0.07 < Operating cash flow per share per price, % of 1.00
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 5.94
- Negative: Inventory ratio change, % of 1.04 > 0.80
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term ALNY quotes
Long-term ALNY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,828.29MM | $2,248.24MM | $3,713.94MM |
| Operating Expenses | $2,110.47MM | $2,425.13MM | $3,212.36MM |
| Operating Income | $-282.18MM | $-176.88MM | $501.58MM |
| Non-Operating Income | $-151.34MM | $-200.49MM | $-178.43MM |
| Interest Expense | $121.22MM | $141.86MM | $252.63MM |
| R&D Expense | $1,004.41MM | $1,126.23MM | $1,324.48MM |
| Income(Loss) | $-433.52MM | $-377.38MM | $323.15MM |
| Taxes | $6.72MM | $-99.22MM | $9.40MM |
| Profit(Loss)* | $-440.24MM | $-278.16MM | $313.75MM |
| Stockholders Equity | $-220.64MM | $67.09MM | $789.18MM |
| Inventory | $89.15MM | $78.51MM | $82.72MM |
| Assets | $3,829.88MM | $4,239.98MM | $4,966.33MM |
| Operating Cash Flow | $104.16MM | $-8.31MM | $524.08MM |
| Capital expenditure | $62.21MM | $34.28MM | $58.70MM |
| Investing Cash Flow | $-336.35MM | $-116.84MM | $436.33MM |
| Financing Cash Flow | $172.13MM | $294.16MM | $-305.19MM |
| Earnings Per Share** | $-3.52 | $-2.18 | $2.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.